学会速報レポート
国内外の主要学会で発表された注目演題について、臨床的位置づけ、試験デザイン、主要結果、安全性、今後の示唆をOncoTribune Evidence Hubの形式で整理しています。
進行肝細胞癌におけるTARE後のアテゾリズマブ+ベバシズマブ逐次投与と全生存期間の関連:傾向スコアマッチング解析
Sequential Transarterial Radioembolization and Atezolizumab plus Bevacizumab Improves Survival in Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
G-HOPE-001:CLDN18.2 ADC arcotatug tavatecan、既治療胃癌でOS・PFSの二重主要評価項目を達成
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician's choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study
CheckMate 8HW最終OS解析:ニボルマブ+イピリムマブ、5年OS率77%で長期生存ベネフィットを確認
Final Overall Survival Results from CheckMate 8HW: Nivolumab plus Ipilimumab vs Nivolumab or Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
EMERALD-1 OS最終解析:TACE+durvalumab+bevacizumabはPFSを改善するも、OS延長は示さず
Overall survival (OS) in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) and transarterial chemoembolisation (TACE) in participants (pts) with unresectable embolisation-eligible hepatocellular carcinoma (eeHCC)
TACE適応HCCに対するSTRIDEベース治療+TACE、mRECIST解析でも一貫した有効性を示す
Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)
KRYSTAL-10:Adagrasib+cetuximabは奏効率で化学療法を上回るも、二重主要評価項目は達成せず
Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRAS G12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial
CheckMate 9DWアップデート:Nivolumab+Ipilimumabの4年生存率は31%―深い奏効と長期無治療生存を確認
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW
IMbrave150の探索的解析:切除不能肝細胞癌患者において、奏効深度(DpR)と奏効期間(DoR)は全生存期間(OS)と関連する
Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150